Author/Year | n/ Country | n (Female/Male) | Age (years) | Project Design | Intervention Methodology | Nature of S/RSD | Intervention Groups | Follow-Up | Periodontal Maintenance | Adverse Events |
---|---|---|---|---|---|---|---|---|---|---|
Mascarenhas et al. 2005 [28] | 30/ USA | AZI: 15 (4/11) C: 15 (7/8) | AZI: 47.0 ± 10.1 C: 45.3 ± 10.8 | Parallel, Single Blinded | AZI: Post therapy, End of S/RSD, in 2 sessions within 14 days C: S/RSD in 2 sessions within 14 days. | Qu S/RSD(2 sessions) | AZI: 500 g × 1 day + 250 g × 4 days C: S/RSD | 3, 6 months from baseline | 3rd, 6th months by examiner | Not reported |
Gomi et al. 2007 [25] | 34/ Japan | AZI: 17 (9/8) C: 17 (9/8) | AZI: 45.4 ± 14.3, C: 51.0 ± 8.8, | not described | AZI: Pre-therapy, 3 days prior to S/RSD C: S/RSD in 4–6 times, weekly intervals | FMD | AZI: 500 g × 3 days C: S/RSD | 1, 3, 6 months from baseline | Weekly by Dental Hygienist | Diarrhoea (n = 1) |
Haffajee et al. 2007 [32] | 48/ USA | AZI: 25 (10/15), C: 23 (7/16) | AZI:47 ± 14, C:43 ± 15 | Parallel. Single Blinded | AZI: Pretherapy, Start of Quadrant Wise S/RSD C: S/RSD in 4 weekly intervals | Qu S/RSD (4 sessions) | AZI: 500 g × 3 days C: S/RSD | 1, 3, 6, 12 months from baseline | 1st, 3rd, 6th and 12th months | Difficulty in swallowing (n = 1) Allergic reaction (n = 1) |
Yashima et al. 2009 [27] | 30/ Japan | AZI 1: 10 (6/4), AZI 2: 10 (5/5), C: 10 (4/6) | AZI 1: 51.1 ± 11.6, AZI 2: 50.8 ± 14.2, C: 51.0 ± 10.6 | not described | AZI 1: Pre therapy 3 days prior to S/RSD (Full Mouth) AZI 2: Pre therapy 3 days prior to S/RSD. Conducted in 3 times, within 7 days C: S/RSD in 6 sessions with 1 week interval | FMD Qu S/RSD (3 sessions) | AZI 1: 500 g × 3 days AZI 2: 500 g × 3 days C: S/RSD | 1, 3, 6, 9, 12 months from baseline | Once a month by the Dental Hygienist | Diarrhoea (n = 1) |
Oteo et al. 2010 [30] | 28/ Spain | AZI: 15 (8/7), C: 13 (5/8) | AZM: 46.6, C: 7.1 | Parallel, Double Blind, Placebo Controlled. | AZI: Post therapy, End of S/RSD in 2 times, within 7 days C: S/RSD in 2 times, within 7 days. | Qu S/RSD –(2 sessions) | AZI: 500 g × 3 days C: Placebo ×  3 days | 1, 3, 6 months from baseline | 1st, 3rd, 6th months | Diarrhoea n = 1) |
Sampaio et al. 2011 [34] | 40/ Brazil | AZI: 20 (7/13), C: 20 (9/11) | AZI: 44.4 ± 7.42, C: 43.5 ± 5.90 | Parallel, Double Blind, Placebo Controlled | AZI: Post therapy, End of S/RSD in 4–6 times, within 14 days C: S/RSD in 4–6 sessions within 14 days | Qu S/RSD (4–6 sessions) | AZI: 500 g × 5 days C: Placebo ×  3 days | 6, 12 months from baseline | Not reported | Diarrhoea (n = 1); Excessive Sleepiness (n = 3) Headache (n = 1) |
Han et al. 2012 [33] | 28/ Turkey | AZI: 14 (4/10), C: 14 (6/8) | AZI: 46.8 ± 5.1 C: 44.8 ± 5.0 | Parallel, Double Blind, Placebo Controlled | AZI: Post therapy, End of quadrant by quadrant S/RSD in 4 sessions C: Quadrant by quadrant S/RSD in 4 sessions | Qu S/RSD (4 sessions) | AZI: 500 g × 3 days C: Placebo ×  3 days | 1, 3, 6 months from baseline | Not Reported | None |
Fonseca et al. 2015 [29] | 85/ Brazil | AZI 1: 15, C 1: 15 AZI 2: 14, C 2: 13 | 44.6 ± 8.8 | Parallel, double blinded | AZI 1: Pretherapy, Start of full mouth S/RSD. C 1: Full mouth S/RSD within 24 h in 2 sessions. AZI 2: Pretherapy, Start of quadrant S/RSD. C 2: S/RSD per quadrant for 30 min in weekly interval between sessions | 1. FMD (2 sessions in 24 h) 2. Qu S/RSD (4 weekly sessions) | AZI: 500 g × 3 days C: S/RSD alone | 3, 6 months from baseline | Not reported | None |
Martande et al. 2016 [31] | 70/ India | AZI: 35 (14/21), C: 35 (16/19) | AZI: 33.3 ± 7.3 C: 32.6 ± 5.4 | Parallel, Double Blind, Placebo Controlled | AZI: Post-therapy End of S/RSD in 3–5 times within 14 days. C: S/RSD in 3–5 times within 14 days | Qu S/RSD (3–5 sessions) | AZI: 500 g × 3 days C: Placebo ×  3 days | 1, 3, 6, 12 months from baseline | 1st, 3rd, 6th, 12th week |